Metabolic and clinical effects of progestogens

@article{Wiegratz2006MetabolicAC,
  title={Metabolic and clinical effects of progestogens},
  author={Inka Wiegratz and Herbert Kuhl},
  journal={The European Journal of Contraception \& Reproductive Health Care},
  year={2006},
  volume={11},
  pages={153 - 161}
}
  • I. WiegratzH. Kuhl
  • Published 1 January 2006
  • Medicine, Biology
  • The European Journal of Contraception & Reproductive Health Care
Synthetic progestogens differ not only in their hormonal potency, but also in their spectrum of hormonal activities. Beside their progestogenic and anti-oestrogenic effects, they may exert oestrogenic, androgenic, antiandrogenic, glucocorticoid and/or anti-mineralocorticoid activities. Consequently, progestogens may influence various metabolic parameters and modulate oestrogen-induced alterations in lipid metabolism, haemostasis, and various other factors. Progestogens with androgenic… 

Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis

ABSTRACT Introduction: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations.

Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study

  • S. PalaciosE. ColliP. Regidor
  • Medicine, Biology
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2021
The results confirm the beneficial properties of the drospirenone-only pill on a variety of metabolic parameters and on coagulatory parameters, and there was no impact on hemostasis.

Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference

Micronized progesterone and dydrogesterone appear to be the safest options, with lower associated cardiovascular, thromboembolic, and breast cancer risks compared with other progestogens, and are the first-choice options for use in ‘special situations,’ such as in women with high-density breast tissue, diabetes, obesity, smoking, and risk factors for venous throm boembolism.

Hormonal Contraceptives and the Risk of Venous Thrombosis.

It is hypothesized that switching COCs, even when switching from a high- to a low-risk COC, increases the risk of venous thrombosis, and it is important to identify women at risk of VT and advise them on alternative contraception methods.

Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol

Administration of E2V/DNG does not influence lipid and glucose metabolism, while mixed effect are exerted by EE/CMA, both preparations reduce bone metabolism without influencing short-term effect on body composition.

Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk

This review discusses the numerous strategies that have been implemented to reduce the thrombotic risk associated with combined oral contraceptives (COCs) from their arrival on the market until today and considers the endogenous thrombin potential-based APC resistance assay.

Micronized progesterone, progestins, and menopause hormone therapy

A narrative review on the balance between benefit/risk using P versus PGs in menopause hormone therapy (MHT) is conducted to aid clinician to choose the best regimens, specifically the PG component of hormone therapy, for women with bothersome menopausal symptoms and with a uterus.

References

SHOWING 1-10 OF 23 REFERENCES

Effects of progestogens on haemostasis.

  • H. Kuhl
  • Medicine, Biology
    Maturitas
  • 1996

Clinical profile of contraceptive progestins

  • G. BenagianoF. PrimieroM. Farris
  • Biology, Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2004
It has been amply proven that - even when administered in doses that do not constantly inhibit ovulation - a progestin can still remain effective as a contraceptive by acting at the level of the cervical mucus and, at least in part, of the endometrium.

Pharmacology of estrogens and progestogens: influence of different routes of administration

  • H. Kuhl
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2005
This review comprises the pharmacokinetics and pharmacodynamics of natural and synthetic estrogens and progestogens used in contraception and therapy, with special consideration of hormone

Sex Steroids Used in Hormonal Treatment Increase Vascular Procoagulant Activity by Inducing Thrombin Receptor (PAR-1) Expression: Role of the Glucocorticoid Receptor

It is demonstrated that several progestins markedly potentiate the vascular procoagulant effects of thrombin by increasing the availability of membraneThrombin receptors in the smooth muscle, an effect that is most likely due to their glucocorticoid-like activity.

Drospirenone, a progestogen with antimineralocorticoid properties: a short review

  • W. Oelkers
  • Medicine, Biology
    Molecular and Cellular Endocrinology
  • 2004

Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.

The indication of a lower or a lack of VTE risk associated with the use of progestin-only contraceptives and with transdermal HRT suggests that these therapies may be safer than combination oral contraceptive pills and oral HRT for women in whom oral estrogen therapy is considered contraindicated.